{
    "id": 412,
    "fullName": "KDR Q472H",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "KDR (VEGFR2) Q472H does not lie within any known functional domains of the Kdr (Vegfr2) protein (UniProt.org). Q472H confers a gain of function to the Kdr (Vegfr2) protein, resulting in increased phosphorylation of Kdr (Vegfr2) in cell culture, increased serum VEGF levels, and increased microvessel density in tumor samples (PMID: 21712447, PMID: 26631613).",
            "references": [
                {
                    "id": 4818,
                    "pubMedId": 26631613,
                    "title": "Identification of a Novel Pathogenic Germline KDR Variant in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26631613"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 20,
                    "pubMedId": 21712447,
                    "title": "Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21712447"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 3791,
        "geneSymbol": "KDR",
        "terms": [
            "KDR",
            "CD309",
            "FLK1",
            "VEGFR",
            "VEGFR2"
        ]
    },
    "variant": "Q472H",
    "createDate": "04/21/2014",
    "updateDate": "09/13/2018",
    "referenceTranscriptCoordinates": {
        "id": 102207,
        "transcript": "NM_002253",
        "gDna": "chr4:g.55106807T>A",
        "cDna": "c.1416A>T",
        "protein": "p.Q472H",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 5324,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cells harboring KDR (VEGFR2) Q472H demonstrated increased sensitivity to treatment with a VEGFR2 (KDR) function-blocking antibody compared to cells with wild-type KDR (VEGFR), resulting in decreased proliferation and invasion in culture (PMID: 26631613).",
            "molecularProfile": {
                "id": 641,
                "profileName": "KDR Q472H"
            },
            "therapy": {
                "id": 3842,
                "therapyName": "unspecified VEGFR2 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4818,
                    "pubMedId": 26631613,
                    "title": "Identification of a Novel Pathogenic Germline KDR Variant in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26631613"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7758,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In clinical case study, a patient with olfactory neuroblastoma harboring EGFR R521K, FGFR2 M186T, KDR Q472H, KDR V297I, and RET M1009T demonstrated sensitivity to the combination of Sutent (sunitinib) and Erbitux (cetuximab), resulting in a complete response (PMID: 27149458).",
            "molecularProfile": {
                "id": 26023,
                "profileName": "EGFR R521K FGFR2 M186T KDR V297I KDR Q472H RET M1009T"
            },
            "therapy": {
                "id": 4568,
                "therapyName": "Cetuximab + Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 369,
                "name": "olfactory neuroblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6481,
                    "pubMedId": 27149458,
                    "title": "Recurrent Olfactory Neuroblastoma Treated With Cetuximab and Sunitinib: A Case Report.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27149458"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 641,
            "profileName": "KDR Q472H",
            "profileTreatmentApproaches": [
                {
                    "id": 270,
                    "name": "VEGFR Inhibitor (Pan)",
                    "profileName": "KDR Q472H"
                },
                {
                    "id": 261,
                    "name": "VEGFR2 Inhibitor",
                    "profileName": "KDR Q472H"
                }
            ]
        },
        {
            "id": 26023,
            "profileName": "EGFR R521K FGFR2 M186T KDR V297I KDR Q472H RET M1009T",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 102207,
            "transcript": "NM_002253",
            "gDna": "chr4:g.55106807T>A",
            "cDna": "c.1416A>T",
            "protein": "p.Q472H",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}